Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 INTRODUCTION Insulin therapy is essential for the treatment of type 1 diabetes (T1D) and may be needed in type 2 diabetes (T2D). Currently available mealtime insulin analogues are effective, have a more physiological profile, and are associated with a lower risk of hypoglycaemia, but they are expensive.1 Insulin aspart is a rapid-acting insulin marketed as NovoLog (Ref-InsAsp-US) in the United States and NovoRapid (Ref-InsAsp-EU) in the European Union (EU).
ORIGINAL ARTICLE Thomas C. Blevins MD Corresponding Author E-mail address: Texas Diabetes and Endocrinology, Austin, Texas, USA Correspondence Thomas C.
Insulin glargine is a long‐acting human insulin analogue that can be administered once daily in patients with type 2 diabetes mellitus (T2DM). MYL‐1501D is a proposed biosimilar or follow‐on biologic to marketed insulin glargine. This study assessed noninferiority of MYL‐1501D to reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, NJ) based on change in glycosylated hemoglobin (HbA 1c ).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
